Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

By D. Corti, Jincun Zhao, M. Pedotti, L. Simonelli, S. Agnihothram, Craig A. Fett, B. Fernandez-Rodriguez, Mathilde Foglierini, Gloria Agatic, Fabrizia Vanzetta and 9 more. 2015

235 citations recorded by the source corpus.

Subfields: Animal Science and Zoology, Immunology, Infectious Diseases

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Animal Science and Zoology

In Immunology

In Infectious Diseases

Citations in the corpus

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, positive): “Passive administration of these Abs protected mice from lethal challenges with MERSCoV, SARS-CoV, and closely related viruses, indicating that they represent a promising therapeutic strategy against coronaviruses (Corti et al., 2015; Menachery et al., 2015; 2016; Rockx et al., 2008).”
Structural insights into coronavirus entry (2019, result): “Specifically, SARS-CoV and MERS-CoV S structures in complex with neutralizing antibodies isolated from survivors showed both antibodies competitively blocked receptor interaction, in agreement with previous surface plasmon resonance data (Corti et al., 2015; Rockx et al., 2008; Traggiai et al., 2004”
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein (2020, background): “For instance, entry of the MERS-CoV-related bat coronavirus HKU4 into human cells required addition of exogenous trypsin, indicating that S proteolytic activation of this bat virus did not occur in human cells (despite its ability to recognize human DPP4)(Wang et al., 2014; Yang et al., 2014).”
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells (2020, unknown): “The method has led to efﬁcient isolation of neutralizing mAbs in various infectious diseases, including HIV and MERS (Scheid et al., 2009; Wang et al., 2018).”
From SARS to MERS, Thrusting Coronaviruses into the Spotlight (2019, methodology): “These methods mainly involve peptidic fusion inhibitors [56, 63, 116, 130] , anti-MERS-CoV neutralizing mAbs [86, 131] , anti-DPP4 mAbs [86, 132, 133] , DPP4 antagonists [134] , and protease inhibitors [135] [136] [137] .”
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays (2020, background): “Indeed, for other coronaviruses, neutralizing antibodies are protective in mouse models of infection [16–20] and associated with at least some reduced susceptibility to re-infection or disease in humans [15,21,22].”
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen (2017, background): “As the primary glycoprotein on the surface of the viral envelope, S proteins are the major target of neutralizing antibodies elicited by natural infection and are key antigens in experimental vaccine candidates (11, 21, 22).”
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein (2019, unknown): “patients [17], hybridoma fusion of B cells from immu nized transgenic mice encoding human variable immu noglobulin domains [18 20], and phage or yeast display”
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion (2020, unknown): “, England1, EMC/2012, and Jordan-N3/ 2012) (Corti et al., 2015).”
SARS and MERS: recent insights into emerging coronaviruses (2016, unknown): “…is directed against the receptor-binding domain of the MERS-CoV spike protein, 1 day after MERS-CoV challenge, and this treat-ment also decreased viral titres in the lungs 124 , as did the neutralizing antibody LCA60, which was obtained from a convalescent patient and produced recombi-nantly 125 .”